Jacobo Mintzer to Middle Aged
This is a "connection" page, showing publications Jacobo Mintzer has written about Middle Aged.
Connection Strength
0.340
-
Dementia in the incarcerated population: a retrospective study using the South Carolina Alzheimer's disease registry, USA. Int J Prison Health. 2023 02 27; ahead-of-print(ahead-of-print).
Score: 0.061
-
Establishment of a predominantly African-American cohort for the study of Alzheimer's disease: the South Carolina Alzheimer's disease clinical core. Dement Geriatr Cogn Disord. 2009; 27(4):329-36.
Score: 0.023
-
Notably higher rates of vascular risk factors and dementia among African Americans in South Carolina: opportunities for public health intervention. J S C Med Assoc. 2008 Oct; 104(7):219-22.
Score: 0.022
-
Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry. 2007 Nov; 15(11):918-31.
Score: 0.021
-
Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial. Am J Geriatr Psychiatry. 2006 Mar; 14(3):280-91.
Score: 0.019
-
A comparison of extrapyramidal symptoms in older outpatients treated with quetiapine or risperidone. Curr Med Res Opin. 2004 Sep; 20(9):1483-91.
Score: 0.017
-
Elderly veterans with combat-related posttraumatic stress disorder in specialty care. J Nerv Ment Dis. 2004 Jan; 192(1):75-9.
Score: 0.016
-
Rivastigmine Transdermal Patch Treatment for Moderate to Severe Cognitive Impairment in Veterans with Traumatic Brain Injury (RiVET Study): A Randomized Clinical Trial. J Neurotrauma. 2021 07 15; 38(14):1943-1952.
Score: 0.013
-
Zolpidem for the treatment of agitation in elderly demented patients. J Clin Psychiatry. 1996 Aug; 57(8):372-3.
Score: 0.010
-
Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial. Am J Psychiatry. 2016 May 01; 173(5):465-72.
Score: 0.009
-
A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation. J Pharmacokinet Pharmacodyn. 2016 Feb; 43(1):99-109.
Score: 0.009
-
A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015 Oct 20; 85(16):1383-91.
Score: 0.009
-
Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial. JAMA. 2015 Sep 22-29; 314(12):1242-54.
Score: 0.009
-
Is sertraline treatment or depression remission in depressed Alzheimer patients associated with improved caregiver well being? Depression in Alzheimer's Disease Study 2. Am J Geriatr Psychiatry. 2014 Jan; 22(1):14-24.
Score: 0.008
-
Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA. 2014 Jan 01; 311(1):33-44.
Score: 0.008
-
Attentional functioning in patients with posttraumatic stress disorder: a preliminary study. CNS Spectr. 2013 Apr; 18(2):90-4.
Score: 0.008
-
Daughters caregiving for Hispanic and non-Hispanic Alzheimer patients: does ethnicity make a difference? Community Ment Health J. 1992 Aug; 28(4):293-303.
Score: 0.007
-
Prevalence of depressive symptoms among white and African-American caregivers of demented patients. Am J Psychiatry. 1992 Apr; 149(4):575-6.
Score: 0.007
-
Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. Proc Natl Acad Sci U S A. 2012 Mar 06; 109(10):3985-90.
Score: 0.007
-
Sertraline for the treatment of depression in Alzheimer disease: genetic influences. J Geriatr Psychiatry Neurol. 2011 Dec; 24(4):222-8.
Score: 0.007
-
Apolipoprotein E and gray matter volume loss in patients with mild cognitive impairment and Alzheimer disease. Radiology. 2011 Mar; 258(3):843-52.
Score: 0.007
-
Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008 Feb; 5(1):83-9.
Score: 0.005
-
The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Int J Geriatr Psychiatry. 2007 May; 22(5):475-84.
Score: 0.005
-
Preliminary examination of progression of Alzheimer's disease in a rural Southern African American cohort. Arch Clin Neuropsychol. 2007 Mar; 22(3):405-14.
Score: 0.005
-
Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study. Curr Alzheimer Res. 2007 Feb; 4(1):81-93.
Score: 0.005
-
Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry. 2006 Sep; 14(9):767-76.
Score: 0.005
-
A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. Int J Geriatr Psychiatry. 2004 Jan; 19(1):9-18.
Score: 0.004
-
Safety and benefits of distance-adjusted prefrontal transcranial magnetic stimulation in depressed patients 55-75 years of age: a pilot study. Depress Anxiety. 2004; 19(4):249-56.
Score: 0.004
-
Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology. 2003 Aug 26; 61(4):479-86.
Score: 0.004
-
Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology. 2002 Apr; 26(4):494-504.
Score: 0.004
-
A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease. Neurology. 1999 Apr 12; 52(6):1146-52.
Score: 0.003